NEW YORK--(BUSINESS WIRE)--Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Bioscience (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO)
Bob Proulx, Executive Chairman of Imagion Biosystems, said: “We are very pleased to report to our shareholders that the tax incentive funds have been received and that the rebate came in higher than the A$1.7 million we originally expected. This cash infusion will significantly enhance our ability to advance the development of our ground-breaking diagnostic imaging technology which was recently designated by the U.S. Food and Drug Administration as a ‘Breakthrough Device’”.
About Manhattan Scientifics Inc.
Manhattan Scientifics is focused on the commercialization of disruptive technologies
This press release contains forward looking statements which are subject 5to a number of risks, assumptions and uncertainties. Mgt believes that purchase of our shares should be considered to be at the high end of the risk spectrum.